What Does "Minimal Manipulation" Mean, and Why Is It the Line Between an FDA-Approved and Unapproved Stem Cell Product?

What This Article Covers

Nearly every legal dispute between the FDA and a stem cell clinic comes down to two technical phrases buried in a federal regulation: "minimal manipulation" and "homologous use." This article explains what those terms mean under 21 CFR 1271.10, why they determine whether a stem cell product can be sold with no FDA premarket review at all or must go through the same rigorous approval pathway as a new drug, and how real court cases and FDA enforcement actions have applied this test to clinics offering fat-derived "stem cell" injections. Understanding this one regulatory fork is one of the most useful things a patient can know before a consultation with any stem cell clinic.

The Two-Part Legal Test Hiding in Plain Sight

Under the Public Health Service Act, human cells, tissues, and cellular and tissue-based products (HCT/Ps) can be regulated one of two ways. Most fall solely under Section 361 of the Act — a lighter-touch framework focused on preventing disease transmission, with no requirement to prove safety or effectiveness before marketing. Others are regulated as drugs, devices, or biologics under Section 351, meaning the manufacturer must obtain FDA premarket approval — typically a Biologics License Application (BLA) — backed by clinical trial data before the product can be sold.

Which bucket a product falls into is governed by 21 CFR 1271.10(a), which lists four criteria an HCT/P must meet to qualify for the lighter Section 361 pathway: (1) it is minimally manipulated; (2) it is intended for homologous use only; (3) its manufacture does not involve combining the cells or tissue with another article, aside from narrow exceptions like water, crystalloids, or sterilizing agents; and (4) it either has no systemic effect and isn't dependent on living cells' metabolic activity for its primary function, or if it does, it's restricted to autologous use, use in a close blood relative, or reproductive use. Fail any one of these four and the product legally needs full premarket approval — no exceptions. In practice, the first two criteria are where nearly every enforcement dispute plays out.

What Counts as "Minimal" vs. "More Than Minimal" Manipulation

FDA's guidance document, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (issued 2017, finalized 2020), defines minimal manipulation differently depending on what's processed. For structural tissue — bone, skin, blood vessels — it means processing that does not alter the tissue's original relevant characteristics relating to its use for reconstruction, repair, or replacement (21 CFR 1271.3(f)(1)). For cells or nonstructural tissue, it means processing that does not alter relevant biological characteristics like differentiation state or proliferation potential (21 CFR 1271.3(f)(2)).

The guidance offers concrete examples: threading bone into a screw is minimal manipulation, but demineralizing it with acid is not, because that changes its structural properties. Concentrating hematopoietic stem cells from blood without expanding them is minimal; culturing those cells with growth factors to multiply their numbers is more than minimal, because expansion itself changes their self-renewal capacity.

The example most relevant to patients involves fat. FDA's guidance explains that when stromal vascular fraction (SVF) is isolated from adipose tissue through enzymatic digestion or mechanical disruption, the agency evaluates that processing against the structural-tissue definition, because fat tissue's original function is structural (cushioning, support). Digesting away the fat and connective matrix to isolate SVF cells destroys those very structural characteristics. FDA has therefore concluded this processing generally constitutes more than minimal manipulation, regardless of whether the isolated cells look biologically unchanged under a microscope.

Why the Line Matters: Two Very Different Regulatory Roads

This distinction is not academic. A product satisfying all four 1271.10(a) criteria can be used clinically without ever submitting data showing it works or is safe at scale — FDA's oversight is limited to donor screening, infectious-disease testing, and good tissue practices. A product that fails even one criterion is legally a drug or biologic, and marketing it without an approved BLA or IND violates the Federal Food, Drug, and Cosmetic Act, exposing the seller to warning letters, injunctions, and criminal referral. There is no size-of-clinic exception.

Real Enforcement and Court Cases Built on This Exact Line

This is not hypothetical — it has been the explicit battleground in major FDA actions. In May 2019, the FDA publicly notified R3 Stem Cell, LLC, of Scottsdale, Arizona, and roughly 50 affiliated clinics that their marketed products for conditions including Lyme disease, Parkinson's disease, ALS, stroke, and dementia would be regulated as unapproved drugs and biologics, since the agency determined they did not meet the Section 361 exemption criteria.

The most significant court test came in United States v. California Stem Cell Treatment Center, Inc. (also involving affiliated Cell Surgical Network clinics). After a district court initially sided with the clinics, the Ninth Circuit reversed on September 27, 2024, holding that the clinics' SVF product — fat enzymatically digested and centrifuged, then reinjected the same day — is an FDA-regulated drug because it doesn't qualify for the narrow "same surgical procedure" exception, and its extensive processing exceeds what minimal manipulation and homologous use permit. This aligned the Ninth Circuit with the D.C. and Eleventh Circuits. The U.S. Supreme Court declined to hear a further appeal on October 15, 2025, leaving the ruling — and FDA's authority over SVF clinics — intact.

Worth pairing with these cautionary cases is a legitimate counterexample: MACI, an FDA-approved therapy (BLA 125603, approved 2016) made from a patient's own cartilage cells, required full BLA approval precisely because culture-expanding those cells before implantation is more than minimal manipulation — the same principle that puts most clinic SVF injections outside the law instead routed MACI through rigorous, evidence-based approval.

How You Can Use This Test to Evaluate Any Clinic's Claims

This framework gives patients a genuinely practical screening tool. If a clinic's product involves enzymatic or mechanical isolation of cells from fat (SVF), any culture-expansion step to grow cell numbers, or use of cells for a function different from what that tissue does in its original location — say, injecting fat-derived cells into a joint or spine to treat arthritis or a neurological condition (non-homologous use) — it is very likely operating outside the Section 361 exemption. A direct question worth asking any clinic: "Is this product FDA-approved, or offered under an Investigational New Drug application, or is it unapproved?" A clinic offering same-day fat-derived injections for arthritis, autism, or neurological disease is, based on FDA's own guidance and the Ninth Circuit's 2024 ruling, very likely on the unapproved side of this line.

Bottom Line

"Minimal manipulation" and "homologous use" are not vague marketing terms — they are precise, litigated legal criteria under 21 CFR 1271.10 that separate lightly regulated tissue products from unapproved drugs. The honest reality is that most fat-derived, enzymatically processed "stem cell" products marketed at U.S. clinics fail this test, a conclusion FDA has stated in guidance and enforcement actions and the Ninth Circuit affirmed in 2024 (left standing by the Supreme Court in 2025). That reality is sobering, but also empowering: this two-part test converts a maze of jargon into a short, concrete checklist any patient can use to ask a clinic the right question before agreeing to treatment.